Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Second Quarter Earnings
October 05 2006 - 5:51PM
PR Newswire (US)
NEW YORK, Oct. 5 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX), an international manufacturer and marketer of
pharmaceutical products, will release its Fiscal 2007 Second
Quarter financial results before the U.S. stock market opens on
Tuesday, October 17, 2006. Later that day, at 10:00 AM EDT, Forest
will host a conference call where Kenneth Goodman, President and
Chief Operating Officer and Frank Perier, Senior Vice President and
Chief Financial Officer, will discuss the financial results and
relevant company and industry topics. The conference call will be
webcast live beginning at 10:00 AM EDT on the Company's website
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until October 31, 2006 at both
websites and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), ID 8085488. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) About
Forest Laboratories and Its Products Forest Laboratories
(http://www.frx.com/) is a US-based pharmaceutical company
dedicated to identifying, developing, and delivering products that
make a positive difference in peoples' lives. Forest Laboratories'
growing product line includes Lexapro(R) (escitalopram oxalate), an
SSRI indicated for adults for the initial and maintenance treatment
of major depressive disorder and for generalized anxiety disorder;
Namenda(R) (memantine HCl), an N-methyl- D-aspartate
(NMDA)-receptor antagonist indicated for the treatment of moderate
and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil),
an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan
medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated
in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation. Except for the historical
information contained herein, this release contains forward looking
statements that involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, acceptance
and demand for new pharmaceutical products, the impact of
competitive products and pricing, the timely development and launch
of new products and the risk factors listed from time to time in
the Company's SEC reports, including the Company's Annual Report on
Form 10-K for the fiscal year ended March 31, 2006 and quarterly
report filed on Form 10-Q for the period ended June 30, 2006. *
Benicar is a registered trademark of Daiichi Sankyo, and Campral is
a registered trademark of Merck Sante s.a.s., subsidiary of Merck
KGaA, Darmstadt, Germany.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles E. Triano, Vice
President - Investor Relations of Forest Laboratories, Inc.,
+1-212-224-6714, Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024